FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385667008> ?p ?o ?g. }

• W4385667008 endingPage "e55581a7" @default.
• W4385667008 startingPage "e55581a7" @default.
• W4385667008 abstract "Background: Chronic myelomonocytic leukaemia (CMML) is a clonal myeloid neoplasm characterised by malignant monocytosis and myeloid dysplasia, dominated by somatic mutations in epigenetic, splicing and signalling genes. While ASXL1 mutations have been associated with poor prognosis in CMML, TET2 mutations seem to imprint a relative survival advantage, especially amongst ASXL1-wild type patients. Since ASXL1 and TET2 are among the most common mutations in CMML, we investigated whether the prognostic impact of mutated ASXL1 can be partially mitigated by concurrent TET2 mutation, with incorporation of its allele burden for outcome prognostication. Aims: This study aims to investigate the clinical relevance of TET2 variant allele fraction (VAF) in CMML patients harboring different ASXL1/TET2 compound genotypes, to improve risk-stratification. Methods: We retrospectively analysed data for 137 CMML patients treated at the Christie Hospital (2006-2021), for whom biobanked genomic DNA was available, and adopted TruSight myeloid sequencing panel and HiSeq platform to analyse the gene alterations. A cohort of 89 CMML patients from the Cleveland Clinic was enrolled for validation. Results: Overall, the median age of the 137 CMML patients was 75 years. Ninety-nine patients (72.2%) had CMML-1, and 45.3% proliferative-type CMML. TET2 was the most frequently mutated gene (66%), followed by SRSF2 (46%) and ASXL1 mutations (45%), as expected. Overall, 140 TET2 mutations were identified in 90 patients and 47 (52%) patients carried multiple TET2 mutations. Median TET2 VAF was 43.5% (range, 4–96.4%) for all TET2 mutations. Patients were divided into high vs low TET2 VAF with median as a cut-off. TET2highVAFpatients were more likely to have proliferative-CMML (p=0.086) and higher absolute neutrophil count (p=0.073). No significant difference regarding other clinical features, disease risks and genomic makeup was found. Median overall survival (OS) of the entire cohort was 36 months and was well stratified by CMML-specific prognostic scoring, CPSS-Molecular risk, and the Mayo Prognostic Model status (respective p, <0.001, 0.002, and 0.001). TET2-mutated patients had better leukaemia-free survival (LFS) and OS than TET-wild type patients. Moreover, concurring with recent studies, patients with ≥2 TET2 mutations had a superior OS comparing to both TET2-single mutant (p=0.001) and TET2-unmutated patients (p=0.002). OS was comparable between the TET2highVAF vs TET2lowVAF patients (p=0.65). However, analysis integrating ASXL1 mutation status and TET2 VAF revealed that ASXL1 mutations conferred poorer OS in TET2highVAF patients (median, 27.6 vs 98.9 months, p=0.002) but not in TET2lowVAF patients (median, 40.6 vs 46.9 months, p=0.683) (Figure 1). This finding was reproducible in the external validation cohort (TET2highVAF and TET2lowVAF groups, p=0.041 and p=0.344, respectively). Time-dependent ROC curve analyses showed that integrating TET2 VAF with ASXL1 mutation could be complementary to current risk stratification systems in predicting LFS/OS of CMML patients. Finally, ASXL1/TET2highVAF was identified as an independent adverse prognostic factor by multivariable analysis, irrespective of age, risk stratification systems, and other mutations (SETBP1, NRAS, RUNX1). Conclusion: We observe that the compound genotype of ASXL1 mutation accompanied by a high mutant TET2 allele burden identified a distinct CMML population with significantly reduced survival, with independent prognostic relevance extrapolated to and validated in an independent cohort. Prospective and large-scale studies are warranted to support these observations and experimental studies are needed to ascertain the underlying mechanistic basis. Figure 1Keywords: TET2, Chronic myelomonocytic leukemia, ASXL1, Prognosis" @default.
• W4385667008 created "2023-08-09" @default.
• W4385667008 creator A5000152081 @default.
• W4385667008 creator A5019235395 @default.
• W4385667008 creator A5035317323 @default.
• W4385667008 creator A5053367862 @default.
• W4385667008 creator A5059441718 @default.
• W4385667008 creator A5082685876 @default.
• W4385667008 creator A5085974329 @default.
• W4385667008 date "2023-08-01" @default.
• W4385667008 modified "2023-09-27" @default.
• W4385667008 title "P726: TET2 ALLELIC BURDEN IMPRINTS A CONTEXT-DEPENDENT PROGNOSTIC SIGNIFICANCE OF ASXL1 MUTATION IN CHRONIC MYELOMONOCYTIC LEUKAEMIA" @default.
• W4385667008 doi "https://doi.org/10.1097/01.hs9.0000969808.55581.a7" @default.
• W4385667008 hasPublicationYear "2023" @default.
• W4385667008 type Work @default.
• W4385667008 citedByCount "0" @default.
• W4385667008 crossrefType "journal-article" @default.
• W4385667008 hasAuthorship W4385667008A5000152081 @default.
• W4385667008 hasAuthorship W4385667008A5019235395 @default.
• W4385667008 hasAuthorship W4385667008A5035317323 @default.
• W4385667008 hasAuthorship W4385667008A5053367862 @default.
• W4385667008 hasAuthorship W4385667008A5059441718 @default.
• W4385667008 hasAuthorship W4385667008A5082685876 @default.
• W4385667008 hasAuthorship W4385667008A5085974329 @default.
• W4385667008 hasBestOaLocation W43856670081 @default.
• W4385667008 hasConcept C104317684 @default.
• W4385667008 hasConcept C126322002 @default.
• W4385667008 hasConcept C143998085 @default.
• W4385667008 hasConcept C151730666 @default.
• W4385667008 hasConcept C180754005 @default.
• W4385667008 hasConcept C2776689207 @default.
• W4385667008 hasConcept C2777928532 @default.
• W4385667008 hasConcept C2779282312 @default.
• W4385667008 hasConcept C2779343474 @default.
• W4385667008 hasConcept C2780007613 @default.
• W4385667008 hasConcept C2780817109 @default.
• W4385667008 hasConcept C2781087989 @default.
• W4385667008 hasConcept C2781187634 @default.
• W4385667008 hasConcept C501734568 @default.
• W4385667008 hasConcept C502942594 @default.
• W4385667008 hasConcept C54355233 @default.
• W4385667008 hasConcept C71924100 @default.
• W4385667008 hasConcept C86803240 @default.
• W4385667008 hasConceptScore W4385667008C104317684 @default.
• W4385667008 hasConceptScore W4385667008C126322002 @default.
• W4385667008 hasConceptScore W4385667008C143998085 @default.
• W4385667008 hasConceptScore W4385667008C151730666 @default.
• W4385667008 hasConceptScore W4385667008C180754005 @default.
• W4385667008 hasConceptScore W4385667008C2776689207 @default.
• W4385667008 hasConceptScore W4385667008C2777928532 @default.
• W4385667008 hasConceptScore W4385667008C2779282312 @default.
• W4385667008 hasConceptScore W4385667008C2779343474 @default.
• W4385667008 hasConceptScore W4385667008C2780007613 @default.
• W4385667008 hasConceptScore W4385667008C2780817109 @default.
• W4385667008 hasConceptScore W4385667008C2781087989 @default.
• W4385667008 hasConceptScore W4385667008C2781187634 @default.
• W4385667008 hasConceptScore W4385667008C501734568 @default.
• W4385667008 hasConceptScore W4385667008C502942594 @default.
• W4385667008 hasConceptScore W4385667008C54355233 @default.
• W4385667008 hasConceptScore W4385667008C71924100 @default.
• W4385667008 hasConceptScore W4385667008C86803240 @default.
• W4385667008 hasIssue "S3" @default.
• W4385667008 hasLocation W43856670081 @default.
• W4385667008 hasLocation W43856670082 @default.
• W4385667008 hasOpenAccess W4385667008 @default.
• W4385667008 hasPrimaryLocation W43856670081 @default.
• W4385667008 hasRelatedWork W150414551 @default.
• W4385667008 hasRelatedWork W1975253683 @default.
• W4385667008 hasRelatedWork W1988517967 @default.
• W4385667008 hasRelatedWork W2057739827 @default.
• W4385667008 hasRelatedWork W2070922469 @default.
• W4385667008 hasRelatedWork W2223919059 @default.
• W4385667008 hasRelatedWork W2348537836 @default.
• W4385667008 hasRelatedWork W2398340825 @default.
• W4385667008 hasRelatedWork W2989212106 @default.
• W4385667008 hasRelatedWork W4229048233 @default.
• W4385667008 hasVolume "7" @default.
• W4385667008 isParatext "false" @default.
• W4385667008 isRetracted "false" @default.
• W4385667008 workType "article" @default.